{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:50:24Z","timestamp":1767135024167,"version":"build-2238731810"},"publisher-location":"Chichester, UK","reference-count":134,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd010685.pub2","type":"reference-entry","created":{"date-parts":[[2015,2,2]],"date-time":"2015-02-02T21:40:57Z","timestamp":1422913257000},"source":"Crossref","is-referenced-by-count":13,"title":["Retinoic acid post consolidation therapy for high-risk neuroblastoma patients treated with autologous hematopoietic stem cell transplantation"],"prefix":"10.1002","author":[{"given":"Frank","family":"Peinemann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elvira C","family":"van Dalen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doreen A","family":"Kahangire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Berthold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,1,29]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD010685.pub2-BIB1|cit1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0360-3016(02)04506-6","article-title":"Impact of radiotherapy for high-risk neuroblastoma: a Children's Cancer Group study","volume":"56","author":"Haas-Kogan","year":"2003","journal-title":"International Journal of Radiation Oncology Biology Physics"},{"issue":"9","key":"10.1002\/14651858.CD010685.pub2-BIB2|cit2","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1200\/JCO.2000.18.9.1888","article-title":"Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: A Children's Cancer Group study","volume":"18","author":"Maris","year":"2000","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD010685.pub2-BIB4|cit3","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1200\/JCO.2007.13.8925","article-title":"Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study","volume":"27","author":"Matthay","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010685.pub2-BIB3|cit4","unstructured":"Matthay KK Reynolds CP Seeger RC Shimada H Adkins ES Haas-Kogan D Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. Erratum http:\/\/jco.ascopubs.org\/content\/32\/17\/1862.full.pdf 1862 3"},{"issue":"16","key":"10.1002\/14651858.CD010685.pub2-BIB5|cit5","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1056\/NEJM199910143411601","article-title":"Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group","volume":"341","author":"Matthay","year":"1999","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD010685.pub2-BIB6|cit6","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/pbc.21784","article-title":"Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology Group","volume":"52","author":"Park","year":"2009","journal-title":"Pediatric Blood and Cancer"},{"issue":"27","key":"10.1002\/14651858.CD010685.pub2-BIB7|cit7","doi-asserted-by":"crossref","first-page":"6474","DOI":"10.1200\/JCO.2005.05.183","article-title":"Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study","volume":"23","author":"Schmidt","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1002\/14651858.CD010685.pub2-BIB8|cit8","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1200\/JCO.1997.15.11.3330","article-title":"Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer","volume":"15","author":"Adamson","year":"1997","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD010685.pub2-BIB9|cit9","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/pbc.21011","article-title":"A phase 2 trial of all-trans-retinoic acid in combination with interferon-alpha2a in children with recurrent neuroblastoma or Wilms tumor: A Pediatric Oncology Branch, NCI and Children's Oncology Group Study","volume":"49","author":"Adamson","year":"2007","journal-title":"Pediatric Blood and Cancer"},{"key":"10.1002\/14651858.CD010685.pub2-BIB10|cit10","doi-asserted-by":"crossref","unstructured":"Aksoylar S Varan A Vergin C Hazar V Akici F Dagdeviren High-dose chemotherapy and autologous stem cell transplantation in patients with high-risk neuroblastoma: Results of Turkish Pediatric Oncology Group-Neuroblastoma 2003 (TPOG-NBL 2003) protocol. 55th Annual Meeting of the American Society of Hematology, ASH 2013 New Orleans, LA, USA Blood 2013 3411","DOI":"10.1182\/blood.V122.21.3411.3411"},{"key":"10.1002\/14651858.CD010685.pub2-BIB11|cit11","first-page":"69-74, 78","article-title":"Current phase III clinical trials investigating pediatric cancers","volume":"19","author":"Anderson","year":"2005","journal-title":"Oncology"},{"issue":"2","key":"10.1002\/14651858.CD010685.pub2-BIB12|cit12","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3109\/07853899609092941","article-title":"Autologous stem cell transplantation in solid tumours of childhood","volume":"28","author":"Atra","year":"1996","journal-title":"Annals of Medicine"},{"key":"10.1002\/14651858.CD010685.pub2-BIB13|cit13","doi-asserted-by":"crossref","unstructured":"Bagatell R Fisher B Seif AE Huang YS Li Y Desai AV Evaluation of resources used during care of children with high-risk neuroblastoma (HR NBL) via merging of cooperative group trial data and administrative data. 2014 ASCO Annual Meeting Journal of Clinical Oncology 2014 Abstract 10069","DOI":"10.1200\/jco.2014.32.15_suppl.10069"},{"issue":"4","key":"10.1002\/14651858.CD010685.pub2-BIB14|cit14","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s11096-011-9519-9","article-title":"Practical implications for the administration of 13-cis retinoic acid in pediatric oncology","volume":"33","author":"Bauters","year":"2011","journal-title":"International Journal of Clinical Pharmacotherapy"},{"issue":"1","key":"10.1002\/14651858.CD010685.pub2-BIB15|cit15","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1517\/14656566.5.1.71","article-title":"A comparison of current neuroblastoma chemotherapeutics","volume":"5","author":"Castel","year":"2004","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"4","key":"10.1002\/14651858.CD010685.pub2-BIB16|cit16","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/pbc.20705","article-title":"Favorable histology, MYCN-amplified 4S neonatal neuroblastoma","volume":"48","author":"Chan","year":"2007","journal-title":"Pediatric Blood & Cancer"},{"issue":"6","key":"10.1002\/14651858.CD010685.pub2-BIB17|cit17","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1080\/08880010390219858","article-title":"Pneumocystis carinii pneumonia: a late presentation following treatment for stage IV neuroblastoma","volume":"20","author":"Clarke","year":"2003","journal-title":"Pediatric Hematology and Oncology"},{"issue":"4","key":"10.1002\/14651858.CD010685.pub2-BIB18|cit18","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/pbc.22052","article-title":"Hypercalcemia and osteoblastic lesions induced by 13-Cis-retinoic acid mimicking relapsed neuroblastoma","volume":"53","author":"Cross","year":"2009","journal-title":"Pediatric Blood & Cancer"},{"issue":"4","key":"10.1002\/14651858.CD010685.pub2-BIB19|cit19","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ejca.2008.01.010","article-title":"Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age","volume":"44","author":"Kraker","year":"2008","journal-title":"European Journal of Cancer"},{"issue":"4","key":"10.1002\/14651858.CD010685.pub2-BIB20|cit20","first-page":"437","article-title":"Complete objective response of neuroblastoma to biological treatment","volume":"30","author":"Bella","year":"2009","journal-title":"Neuroendocrinology Letters"},{"issue":"17","key":"10.1002\/14651858.CD010685.pub2-BIB21|cit21","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/jnci\/djh268","article-title":"Fenretinide activates a distinct apoptotic pathway","volume":"96","author":"Dmitrovsky","year":"2004","journal-title":"Journal of the National Cancer Institute"},{"issue":"11","key":"10.1002\/14651858.CD010685.pub2-BIB22|cit22","first-page":"1734","article-title":"Stage 4S neuroblastoma, a disseminated tumor with excellent outcome","volume":"27","author":"Elimam","year":"2006","journal-title":"Saudi Medical Journal"},{"issue":"4","key":"10.1002\/14651858.CD010685.pub2-BIB23|cit23","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/mpo.2950200407","article-title":"13-cis-retinoic acid (NSC 122758) in the treatment of children with metastatic neuroblastoma unresponsive to conventional chemotherapy: report from the Childrens Cancer Study Group","volume":"20","author":"Finklestein","year":"1992","journal-title":"Medical and Pediatric Oncology"},{"issue":"4","key":"10.1002\/14651858.CD010685.pub2-BIB24|cit24","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00280-007-0649-7","article-title":"Pharmacokinetics of oral fenretinide in neuroblastoma patients: indications for optimal dose and dosing schedule also with respect to the active metabolite 4-oxo-fenretinide","volume":"62","author":"Formelli","year":"2008","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"5","key":"10.1002\/14651858.CD010685.pub2-BIB25|cit25","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s00280-010-1370-5","article-title":"Relationship among pharmacokinetics and pharmacodynamics of fenretinide and plasma retinol reduction in neuroblastoma patients","volume":"66","author":"Formelli","year":"2010","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"22","key":"10.1002\/14651858.CD010685.pub2-BIB26|cit26","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1200\/JCO.2009.25.9119","article-title":"Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report","volume":"28","author":"Fouladi","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD010685.pub2-BIB27|cit27","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/pbc.24351","article-title":"131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma","volume":"60","author":"French","year":"2013","journal-title":"Pediatric Blood and Cancer"},{"issue":"4","key":"10.1002\/14651858.CD010685.pub2-BIB28|cit28","first-page":"311","article-title":"Retinoids in therapy of neuroblastoma","volume":"20","author":"Frgala","year":"2007","journal-title":"Klinicka Onkologie"},{"issue":"6","key":"10.1002\/14651858.CD010685.pub2-BIB29|cit29","first-page":"2032","article-title":"Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma","volume":"9","author":"Garaventa","year":"2003","journal-title":"Clinical Cancer Research"},{"issue":"5","key":"10.1002\/14651858.CD010685.pub2-BIB30|cit30","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/pbc.24207","article-title":"Feasibility of a tandem autologous peripheral blood stem cell transplant regimen for high risk neuroblastoma in a cooperative group setting: a Pediatric Oncology Group study: a Report from the Children's Oncology Group","volume":"59","author":"Granger","year":"2012","journal-title":"Pediatric Blood and Cancer"},{"issue":"3","key":"10.1002\/14651858.CD010685.pub2-BIB31|cit31","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/BF01405299","article-title":"Hypervitaminosis A as a complication of treatment for neuroblastoma","volume":"26","author":"Grissom","year":"1996","journal-title":"Pediatric Radiology"},{"issue":"2","key":"10.1002\/14651858.CD010685.pub2-BIB32|cit32","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/mpo.10089","article-title":"Sweet syndrome associated with 13-cis-retinoic acid (isotretinoin) therapy","volume":"40","author":"Gyorfy","year":"2003","journal-title":"Medical Pediatric Oncology"},{"key":"10.1002\/14651858.CD010685.pub2-BIB33|cit33","doi-asserted-by":"crossref","unstructured":"Hamidieh AA Beigi D Fallahi B Behfar M Jalili M Hamdi A Comparison of autologous hematopoietic stem cell transplantation with and without metaiodobenzylguanidine (MIBG) in patients with high risk neuroblastoma. 2012 BMT Tandem Meetings San Diego, CA, USA Biology of Blood and Marrow Transplantation 2012 S251","DOI":"10.1016\/j.bbmt.2011.12.138"},{"issue":"4","key":"10.1002\/14651858.CD010685.pub2-BIB34|cit34","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s00467-004-1775-7","article-title":"Retinoic acid may increase the risk of bone marrow transplant nephropathy","volume":"20","author":"Haysom","year":"2005","journal-title":"Pediatric Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD010685.pub2-BIB35|cit35","first-page":"203","article-title":"1st clinical experience with subtoxic vitamin A doses during radiation and cytostatic tumor therapy","volume":"24","author":"Hoefer-Janker","year":"1969","journal-title":"Krebsarzt"},{"key":"10.1002\/14651858.CD010685.pub2-BIB36|cit36","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1507\/endocrj.46.Suppl_S113","article-title":"A case of growth failure caused by 13-CIS-retinoic acid administration after bone marrow transplantation for neuroblasoma","volume":"46 Suppl","author":"Inamo","year":"1999","journal-title":"Endocrine Journal"},{"issue":"4","key":"10.1002\/14651858.CD010685.pub2-BIB37|cit37","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/pbc.21366","article-title":"Chronic metastatic neuroblastoma","volume":"50","author":"Kazanowska","year":"2008","journal-title":"Pediatric Blood & Cancer"},{"issue":"1-2","key":"10.1002\/14651858.CD010685.pub2-BIB38|cit38","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s002800050535","article-title":"Pharmacokinetic studies of 13-cis-retinoic acid in pediatric patients with neuroblastoma following bone marrow transplantation","volume":"39","author":"Khan","year":"1996","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"9","key":"10.1002\/14651858.CD010685.pub2-BIB39|cit39","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1200\/JCO.2002.06.060","article-title":"Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: results of the Chicago Pilot II study","volume":"20","author":"Kletzel","year":"2002","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010685.pub2-BIB40|cit40","unstructured":"Kogner P Borgstr\u00f6m P Karpe B Lundell G Hjelm Skog AL Winiarski J Children with high-risk neuroblastoma may be long-term survivors after application of intensified multimodal therapy. 36th Congress of the International Society of Paediatric Oncology, SIOP 2004, Oslo, Norway, Abstract P.C.005 Pediatric Blood & Cancer 2004 400"},{"issue":"9","key":"10.1002\/14651858.CD010685.pub2-BIB41|cit41","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1054\/bjoc.2000.1425","article-title":"A randomized trial of 13-Cis retinoic acid in children with advanced neuroblastoma after high-dose therapy","volume":"83","author":"Kohler","year":"2000","journal-title":"British Journal of Cancer"},{"issue":"10","key":"10.1002\/14651858.CD010685.pub2-BIB42|cit42","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S1470-2045(13)70309-7","article-title":"Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial","volume":"14","author":"Kreissman","year":"2013","journal-title":"Lancet Oncology"},{"issue":"12","key":"10.1002\/14651858.CD010685.pub2-BIB43|cit43","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1200\/JCO.1994.12.12.2607","article-title":"Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age","volume":"12","author":"Kushner","year":"1994","journal-title":"Journal of Clinical Oncology"},{"issue":"22","key":"10.1002\/14651858.CD010685.pub2-BIB44|cit44","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1200\/JCO.2001.19.22.4189","article-title":"Phase II trial of the anti-GD2 monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma","volume":"19","author":"Kushner","year":"2001","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD010685.pub2-BIB45|cit45","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/sj.bmt.1703213","article-title":"Topotecan combined with myeloablative does of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults","volume":"28","author":"Kushner","year":"2001","journal-title":"Bone Marrow Transplantation"},{"issue":"7","key":"10.1002\/14651858.CD010685.pub2-BIB46|cit46","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/00043426-200307000-00003","article-title":"Curability of recurrent disseminated disease after surgery alone for local-regional neuroblastoma using intensive chemotherapy and anti-G(D2) immunotherapy","volume":"25","author":"Kushner","year":"2003","journal-title":"Journal of Pediatric Hematology\/ Oncology"},{"issue":"6","key":"10.1002\/14651858.CD010685.pub2-BIB47|cit47","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/mpo.10273","article-title":"Neuroblastoma in adolescents and adults: the Memorial Sloan-Kettering experience","volume":"41","author":"Kushner","year":"2003","journal-title":"Medical Pediatric Oncology"},{"key":"10.1002\/14651858.CD010685.pub2-BIB48|cit48","unstructured":"Ladenstein R P\u00f6tschger U Modritz D Schreier G Castel V Michon J The siopen-r-net project: building a european network for neuroblastoma treatment (hr-nbl-1\/esiop trial) and research. 36th Congress of the International Society of Paediatric Oncology, SIOP 2004, Oslo, Norway, Abstract P.C.014 Pediatric Blood & Cancer 2004 402"},{"issue":"5 suppl","key":"10.1002\/14651858.CD010685.pub2-BIB49|cit49","doi-asserted-by":"crossref","first-page":"Abstract 10026","DOI":"10.1200\/jco.2014.32.15_suppl.10026","article-title":"Immunotherapy (IT) with ch14.18\/CHO for high-risk neuroblastoma: First results from the randomised HR-NBL1\/SIOPEN trial. 2014 ASCO Annual Meeting","volume":"32","author":"Ladenstein","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD010685.pub2-BIB50|cit50","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/bmt.2010.182","article-title":"Early clinical indicators of transplant-associated thrombotic microangiopathy in pediatric neuroblastoma patients undergoing auto-SCT","volume":"46","author":"Laskin","year":"2011","journal-title":"Bone Marrow Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD010685.pub2-BIB51|cit51","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11060-005-9062-4","article-title":"Combination chemotherapy with 13-cis-retinoic acid and celecoxib in the treatment of glioblastoma multiforme","volume":"78","author":"Levin","year":"2006","journal-title":"Journal of Neurooncology"},{"key":"10.1002\/14651858.CD010685.pub2-BIB52|cit52","series-title":"European Journal of Cancer","first-page":"S42","article-title":"Retinoids in the treatment of neuroblastoma [Abstract no: 204]","author":"Lie","year":"1993"},{"issue":"2","key":"10.1002\/14651858.CD010685.pub2-BIB53|cit53","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/pbc.21768","article-title":"Hypercalcemia and 13-cis-retinoic acid in post-consolidation therapy of neuroblastoma","volume":"52","author":"Marabelle","year":"2009","journal-title":"Pediatric Blood & Cancer"},{"issue":"9","key":"10.1002\/14651858.CD010685.pub2-BIB54|cit54","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1200\/JCO.2000.18.9.1888","article-title":"Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study","volume":"18","author":"Maris","year":"2000","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD010685.pub2-BIB55|cit55","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s10633-008-9132-y","article-title":"Total rod ERG suppression with high dose compassionate Fenretinide usage","volume":"117","author":"Marmor","year":"2008","journal-title":"Documenta Ophthalmologica"},{"issue":"7","key":"10.1002\/14651858.CD010685.pub2-BIB56|cit56","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/pbc.22986","article-title":"Treatment of advanced neuroblastoma in children over 1 year of age: The critical role of 131I-metaiodobenzylguanidine combined with chemotherapy in a rapid induction regimen","volume":"56","author":"Mastrangelo","year":"2011","journal-title":"Pediatric Blood & Cancer"},{"issue":"4","key":"10.1002\/14651858.CD010685.pub2-BIB57|cit57","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/0959-8049(95)00015-B","article-title":"Role of myeloablative therapy in improved outcome for high risk neuroblastoma: Review of recent Children's Cancer Group results","volume":"31A","author":"Matthay","year":"1995","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD010685.pub2-BIB58|cit58","first-page":"89","article-title":"Current results with myeloablative therapy with hematopoietic support in advanced neuroblastoma","volume":"9","author":"Matthay","year":"1999","journal-title":"Cancer Research Therapy and Control"},{"issue":"9","key":"10.1002\/14651858.CD010685.pub2-BIB59|cit59","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1054\/bjoc.2000.1430","article-title":"Is there a role for retinoids to treat minimal residual disease in neuroblastoma?","volume":"83","author":"Matthay","year":"2000","journal-title":"British Journal of Cancer"},{"issue":"3","key":"10.1002\/14651858.CD010685.pub2-BIB60|cit60","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1200\/JCO.2005.03.6400","article-title":"Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study","volume":"24","author":"Matthay","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD010685.pub2-BIB61|cit61","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1158\/1078-0432.CCR-12-3313","article-title":"Targeted isotretinoin in neuroblastoma: kinetics, genetics, or absorption","volume":"19","author":"Matthay","year":"2013","journal-title":"Clinical Cancer Research"},{"issue":"11","key":"10.1002\/14651858.CD010685.pub2-BIB62|cit62","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1002\/pbc.24643","article-title":"Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed\/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium","volume":"60","author":"Maurer","year":"2013","journal-title":"Pediatric Blood & Cancer"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD010685.pub2-BIB63|cit63","doi-asserted-by":"crossref","first-page":"Abstr 10071","DOI":"10.1200\/jco.2014.32.15_suppl.10071","article-title":"Fenretinide (4-HPR)\/Lym-X-Sorb (LXS) oral powder plus ketoconazole in patients with high-risk (HR) recurrent or resistant neuroblastoma: A new approach to neuroblastoma therapy (NANT) consortium trial. 2014 ASCO Annual Meeting","volume":"32","author":"Maurer","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1002\/14651858.CD010685.pub2-BIB64|cit64","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1093\/jnci\/85.12.939","article-title":"ASCO\/AACR: shared emphases and separate meetings","volume":"85","author":"McCann","year":"1993","journal-title":"Journal of the National Cancer Institute"},{"issue":"4","key":"10.1002\/14651858.CD010685.pub2-BIB65|cit65","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1442-200X.1995.tb03361.x","article-title":"Comprehensive treatment of advanced neuroblastoma involving autologous bone marrow transplant","volume":"37","author":"Mugishima","year":"1995","journal-title":"Acta Paediatrica Japonica"},{"issue":"2","key":"10.1002\/14651858.CD010685.pub2-BIB66|cit66","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1442-200X.2008.02544.x","article-title":"Hypercalcemia induced by 13 cis-retinoic acid in patients with neuroblastoma","volume":"50","author":"Mugishima","year":"2008","journal-title":"Pediatrics International"},{"issue":"6","key":"10.1002\/14651858.CD010685.pub2-BIB67|cit67","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s004310050631","article-title":"Generalized metaphyseal modification with cone-shaped epiphyses following long-term administration of 13-cis-retinoic acid","volume":"156","author":"Nishimura","year":"1997","journal-title":"European Journal of Pediatrixcs"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD010685.pub2-BIB68|cit68","first-page":"140","article-title":"The Turkish Pediatric Oncology Group Neuroblastoma 2003 (TPOG-NB-2003): treatment results of the high risk group. 40th Annual Conference of the International Society of Paediatric Oncology, SIOP 2008, Berlin, Germany, Abstract D110","volume":"50","author":"Olgun","year":"2008","journal-title":"Pediatric Blood and Cancer"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD010685.pub2-BIB69|cit69","doi-asserted-by":"crossref","first-page":"Abstr 10044","DOI":"10.1200\/jco.2014.32.15_suppl.10044","article-title":"A comprehensive safety trial of chimeric antibody 14.18 (ch14.18) with GM-CSF, IL-2, and isotretinoin in high-risk neuroblastoma patients following myeloablative therapy: A Children's Oncology Group study. 2014 ASCO Annual Meeting","volume":"32","author":"Ozkaynak","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010685.pub2-BIB70|cit70","series-title":"Annual Meeting Proceedings of the American Society of Clinical Oncology","first-page":"800","article-title":"Outcome of high risk (HR) stage 3 neuroblastoma (NB) with myeloablative therapy and 13-cis-retinoic acid. Abstracts for the 41th Annual Meeting of the American Society of Clinical Oncology, Orlando, Florida, 13-17 May, 2005 [Abstract No. 8503]","author":"Park","year":"2005"},{"issue":"33","key":"10.1002\/14651858.CD010685.pub2-BIB71|cit71","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.1200\/JCO.2010.34.3293","article-title":"Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study","volume":"29","author":"Park","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD010685.pub2-BIB72|cit72","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1470-2045(08)70069-X","article-title":"High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial","volume":"9","author":"Pearson","year":"2008","journal-title":"Lancet Oncology"},{"issue":"6","key":"10.1002\/14651858.CD010685.pub2-BIB73|cit73","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/pbc.22200","article-title":"Langerhans cell histiocytosis in a patient with stage 4 neuroblastoma receiving oral fenretinide","volume":"53","author":"Rayburg","year":"2009","journal-title":"Pediatric Blood & Cancer"},{"issue":"13","key":"10.1002\/14651858.CD010685.pub2-BIB74|cit74","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/jnci\/91.13.1099","article-title":"Fenretinide: the death of a tumor cell","volume":"91","author":"Reed","year":"1999","journal-title":"Journal of the National Cancer Institute"},{"issue":"3","key":"10.1002\/14651858.CD010685.pub2-BIB75|cit75","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/00043426-200103000-00005","article-title":"Detection of minimal residual disease in bone marrow during or after therapy as a prognostic marker for high-risk neuroblastoma","volume":"23","author":"Reynolds","year":"2001","journal-title":"Journal of Pediatric Hematology\/Oncology"},{"issue":"34","key":"10.1002\/14651858.CD010685.pub2-BIB76|cit76","doi-asserted-by":"crossref","first-page":"8655","DOI":"10.1200\/JCO.2004.00.8128","article-title":"Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group","volume":"23","author":"Richtig","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD010685.pub2-BIB77|cit77","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/bjc.1982.48","article-title":"Trial of an aromatic retinoid in patients with solid tumours","volume":"45","author":"Rustin","year":"1982","journal-title":"British Journal of Cancer"},{"issue":"7","key":"10.1002\/14651858.CD010685.pub2-BIB78|cit78","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/pbc.24173","article-title":"Thiotepa and melphalan based single, tandem, and triple high dose therapy and autologous stem cell transplantation for high risk neuroblastoma","volume":"59","author":"Saarinen-Pihkala","year":"2012","journal-title":"Pediatric Blood & Cancer"},{"issue":"3","key":"10.1002\/14651858.CD010685.pub2-BIB79|cit79","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/pbc.24111","article-title":"13-cis-retinoic acid-associated bone marrow edema in neuroblastoma","volume":"59","author":"Sato","year":"2012","journal-title":"Pediatric Blood & Cancer"},{"issue":"24","key":"10.1002\/14651858.CD010685.pub2-BIB80|cit80","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1200\/JCO.2000.18.24.4067","article-title":"Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children's Cancer Group Study","volume":"18","author":"Seeger","year":"2000","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD010685.pub2-BIB81|cit81","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1055\/s-2005-836518","article-title":"Infants with stage 4 neuroblastoma: the impact of the chimeric anti-GD2-antibody ch14.18 consolidation therapy","volume":"217","author":"Simon","year":"2005","journal-title":"Klinische P\u00e4diatrie"},{"key":"10.1002\/14651858.CD010685.pub2-BIB82|cit82","series-title":"Pediatric Blood & Cancer","first-page":"789","article-title":"Anti-GD2-antibody CH14.18 or retinoic acid as consolidation therapy in high-risk neuroblastoma. 43rd Congress of the International Society of Paediatric Oncology, SIOP 2011 Auckland New Zealand","author":"Simon","year":"2011"},{"issue":"1","key":"10.1002\/14651858.CD010685.pub2-BIB83|cit83","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/pbc.20848","article-title":"Favorable response of intraommaya topotecan for leptomeningeal metastasis of neuroblastoma after intravenous route failure","volume":"50","author":"Sirachainan","year":"2008","journal-title":"Pediatric Blood & Cancer"},{"issue":"1","key":"10.1002\/14651858.CD010685.pub2-BIB84|cit84","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/sj.bmt.1705691","article-title":"Tandem high-dose chemotherapy and autologous stem cell rescue in patients over 1 year of age with stage 4 neuroblastoma","volume":"40","author":"Sung","year":"2007","journal-title":"Bone Marrow Transplantation"},{"issue":"10","key":"10.1002\/14651858.CD010685.pub2-BIB85|cit85","first-page":"770","article-title":"Comprehensive protocol for diagnosis and treatment of childhood neuroblastoma--results of 45 cases","volume":"44","author":"Tang","year":"2006","journal-title":"Zhonghua Er Ke Za Zhi (Chinese Journal of Pediatrics)"},{"issue":"9","key":"10.1002\/14651858.CD010685.pub2-BIB86|cit86","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s004670050693","article-title":"Possible association of retinoic acid with bone marrow transplant nephropathy","volume":"13","author":"Turman","year":"1999","journal-title":"Pediatric Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD010685.pub2-BIB87|cit87","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/sj.bjc.6603554","article-title":"Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma - a study of the United Kingdom Children's Cancer Study Group","volume":"96","author":"Veal","year":"2007","journal-title":"British Journal of Cancer"},{"issue":"2","key":"10.1002\/14651858.CD010685.pub2-BIB88|cit88","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1158\/1078-0432.CCR-12-2225","article-title":"Adaptive dosing approaches to the individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma","volume":"19","author":"Veal","year":"2013","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD010685.pub2-BIB89|cit89","series-title":"Proceedings of the American Society of Clinical Oncology","first-page":"366, Abstract 1","article-title":"Phase I trial of 13-Cis-Retinoic acid (cis-RA) in neuroblastoma patients following bone marrow transplantation (BMT) [abstract]","author":"Villablanca","year":"1992"},{"issue":"4","key":"10.1002\/14651858.CD010685.pub2-BIB90|cit90","first-page":"410","article-title":"Hypercalcemia: a dose-limiting toxicity associated with 13-cis-retinoic acid","volume":"15","author":"Villablanca","year":"1993","journal-title":"American Journal of Pediatric Hematology\/Oncology"},{"issue":"4","key":"10.1002\/14651858.CD010685.pub2-BIB91|cit91","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1200\/JCO.1995.13.4.894","article-title":"Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation","volume":"13","author":"Villablanca","year":"1995","journal-title":"Journal of Clinical Oncology"},{"issue":"21","key":"10.1002\/14651858.CD010685.pub2-BIB92|cit92","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1200\/JCO.2005.03.9271","article-title":"Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709)","volume":"24","author":"Villablanca","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"21","key":"10.1002\/14651858.CD010685.pub2-BIB93|cit93","doi-asserted-by":"crossref","first-page":"6858","DOI":"10.1158\/1078-0432.CCR-11-0995","article-title":"Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR\/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group","volume":"17","author":"Villablanca","year":"2011","journal-title":"Clincal Cancer Research"},{"issue":"3","key":"10.1002\/14651858.CD010685.pub2-BIB94|cit94","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00043426-199705000-00002","article-title":"Pediatric phase II cancer chemotherapy trials: a Pediatric Oncology Group study","volume":"19","author":"Weitman","year":"1997","journal-title":"Journal of Pediatric Hematology\/Oncology"},{"issue":"22","key":"10.1002\/14651858.CD010685.pub2-BIB95|cit95","first-page":"1556","article-title":"Therapeutic experience of childhood stage III neuroblastoma","volume":"90","author":"Ye","year":"2010","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"14","key":"10.1002\/14651858.CD010685.pub2-BIB96|cit96","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","article-title":"Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma","volume":"363","author":"Yu","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1002\/14651858.CD010685.pub2-BIB97|cit97","first-page":"1931","article-title":"Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid","volume":"2","author":"Yung","year":"1996","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD010685.pub2-BIB98|cit98","first-page":"467","article-title":"Therapeutic effects of high dose chemotherapy combined with autologous peripheral blood stem cell transplantation on 18 cases of stage IV neuroblastoma in children","volume":"37","author":"Zhu","year":"2010","journal-title":"Chinese Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010685.pub2-BIB99|cit99","series-title":"Proceedings of the American Society of Clinical Oncology","first-page":"2a, Abstract 5","article-title":"13-CIS-retinoic acid after intensive consolidation therapy for neuroblastoma improves event-free survival: a randomized Children's Cancer Group study. 34th Annual Meeting of the American Society of Clinical Oncology; 16-19 May 1998; Los Angeles, California, USA","author":"Reynolds","year":"1998"},{"key":"10.1002\/14651858.CD010685.pub2-BIB100|cit100","series-title":"Proceedings of the American Society of Clinical Oncology","first-page":"392a, Abstract","article-title":"13-cis-retinoic acid improves overall survival following myeloablative therapy for high-risk neuroblastoma: a randomized Children's Cancer Group study. 38th Annual Meeting of the American Society of Clinical Oncology; 18-21 May 2002; Orlando, Florida, USA","author":"Reynolds","year":"2002"},{"key":"10.1002\/14651858.CD010685.pub2-BIB101|cit101","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/3-540-26616-X_7","article-title":"Clinical presentation","volume-title":"Neuroblastoma","author":"Berthold","year":"2005"},{"issue":"1","key":"10.1002\/14651858.CD010685.pub2-BIB102|cit102","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1148\/radiol.11101352","article-title":"Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project","volume":"261","author":"Brisse","year":"2011","journal-title":"Radiology"},{"issue":"8","key":"10.1002\/14651858.CD010685.pub2-BIB103|cit103","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1200\/JCO.1993.11.8.1466","article-title":"Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment","volume":"11","author":"Brodeur","year":"1993","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010685.pub2-BIB104|cit104","unstructured":"Centers of Disease Control and Prevention (CDC) Clinical growth charts. Birth to 36 months: boys length-for-age and weight-for-age percentiles http:\/\/www.cdc.gov\/growthcharts\/data\/set1clinical\/cj41c017.pdf"},{"key":"10.1002\/14651858.CD010685.pub2-BIB105|cit105","unstructured":"Centers of Disease Control and Prevention Clinical growth charts. 2 to 20 years: boys stature-for-age and weight-for-age percentiles http:\/\/www.cdc.gov\/growthcharts\/data\/set1clinical\/cj41c021.pdf"},{"issue":"2","key":"10.1002\/14651858.CD010685.pub2-BIB106|cit106","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2008.16.6785","article-title":"The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report","volume":"27","author":"Cohn","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD010685.pub2-BIB107|cit107","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1158\/1078-0432.CCR-11-1409","article-title":"New strategies in refractory and recurrent neuroblastoma: translational opportunities to impact patient outcome","volume":"18","author":"Cole","year":"2012","journal-title":"Clininical Cancer Research"},{"key":"10.1002\/14651858.CD010685.pub2-BIB108|cit108","unstructured":"Cancer Therapy Evaluation Program (CTEP) Common Terminology Criteria for Adverse Events (CTCAE) http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_40"},{"issue":"3","key":"10.1002\/14651858.CD010685.pub2-BIB109|cit109","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD010685.pub2-BIB110|cit110","unstructured":"Thomson Reuters EndNote 2012"},{"issue":"1","key":"10.1002\/14651858.CD010685.pub2-BIB111|cit111","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/pbc.20859","article-title":"Neuroblastoma in adults: Incidence and survival analysis based on SEER data","volume":"49","author":"Esiashvili","year":"2007","journal-title":"Pediatric Blood & Cancer"},{"issue":"2","key":"10.1002\/14651858.CD010685.pub2-BIB112|cit112","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G","article-title":"A proposed staging for children with neuroblastoma. Children's cancer study group A","volume":"27","author":"Evans","year":"1971","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD010685.pub2-BIB113|cit113","unstructured":"Genetic and Rare Diseases Information Center (GARD) The Office of Rare Diseases Research (ORDR) Neuroblastoma http:\/\/rarediseases.info.nih.gov\/gard\/7185\/neuroblastoma\/resources\/1"},{"key":"10.1002\/14651858.CD010685.pub2-BIB114|cit114","unstructured":"Goodman MT Gurney JG Smith MA Olshan AF SEER Pediatric Monograph. Sympathetic Nervous System Tumors http:\/\/seer.cancer.gov\/publications\/childhood\/sympathetic.pdf"},{"key":"10.1002\/14651858.CD010685.pub2-BIB115|cit115","unstructured":"McMaster University GRADEpro 2014"},{"issue":"9","key":"10.1002\/14651858.CD010685.pub2-BIB116|cit116","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1200\/JCO.2007.12.3349","article-title":"Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97","volume":"26","author":"Hero","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"7414","key":"10.1002\/14651858.CD010685.pub2-BIB117|cit117","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD010685.pub2-BIB118|cit118","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD010685.pub2-BIB119|cit119","unstructured":"International Clinical Sciences Support Center (ICSSC) WHO Toxicity Grading Scale for Determining The Severity of Adverse Events http:\/\/www.icssc.org\/Documents\/Resources\/AEManual2003AppendicesFebruary_06_2003%20final.pdf"},{"key":"10.1002\/14651858.CD010685.pub2-BIB120|cit120","unstructured":"Kremer LCM van Dalen EC Moher D Caron HN Cochrane Childhood Cancer Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) http:\/\/onlinelibrary.wiley.com\/o\/cochrane\/clabout\/articles\/CHILDCA\/frame.html"},{"issue":"10","key":"10.1002\/14651858.CD010685.pub2-BIB121|cit121","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1158\/1078-0432.CCR-11-1939","article-title":"Promising therapeutic targets in neuroblastoma","volume":"18","author":"Matthay","year":"2012","journal-title":"Clinical Cancer Research"},{"issue":"7","key":"10.1002\/14651858.CD010685.pub2-BIB122|cit122","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Medicine"},{"key":"10.1002\/14651858.CD010685.pub2-BIB123|cit123","unstructured":"National Cancer Institute: PDQ\u00ae Neuroblastoma Treatment. Bethesda, MD: National Cancer Institute. Date last modified 16 November 2012 http:\/\/cancer.gov\/cancertopics\/pdq\/treatment\/neuroblastoma\/HealthProfessional"},{"issue":"24","key":"10.1002\/14651858.CD010685.pub2-BIB124|cit124","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD010685.pub2-BIB125|cit125","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"1-2","key":"10.1002\/14651858.CD010685.pub2-BIB126|cit126","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0304-3835(03)00108-3","article-title":"Retinoid therapy of high-risk neuroblastoma","volume":"197","author":"Reynolds","year":"2003","journal-title":"Cancer Letters"},{"issue":"2","key":"10.1002\/14651858.CD010685.pub2-BIB127|cit127","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/jnci\/73.2.405","article-title":"Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas","volume":"73","author":"Shimada","year":"1984","journal-title":"Journal of the National Cancer Institute"},{"issue":"4","key":"10.1002\/14651858.CD010685.pub2-BIB128|cit128","first-page":"589","article-title":"Retinoic acid-induced growth inhibition and morphologic differentiation of human neuroblastoma cells in vitro","volume":"68","author":"Sidell","year":"1982","journal-title":"Journal of the National Cancer Institute"},{"issue":"1","key":"10.1002\/14651858.CD010685.pub2-BIB129|cit129","doi-asserted-by":"crossref","first-page":"21-30","DOI":"10.1016\/0014-4827(83)90184-2","article-title":"Effects of retinoic acid (RA) on the growth and phenotypic expression of several human neuroblastoma cell lines","volume":"148","author":"Sidell","year":"1983","journal-title":"Experimental Cell Research"},{"key":"10.1002\/14651858.CD010685.pub2-BIB130|cit130","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"5","key":"10.1002\/14651858.CD010685.pub2-BIB131|cit131","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006301.pub2","article-title":"High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma","author":"Yal\u00e7in","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD010685.pub2-BIB132|cit132","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006301.pub3","article-title":"High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma","author":"Yal\u00e7in","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010685.pub2-BIB133|cit133","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1471-2288-12-47","article-title":"Assessment of reporting quality of conference abstracts in sports injury prevention according to CONSORT and STROBE criteria and their subsequent publication rate as full papers","volume":"12","author":"Yoon","year":"2012","journal-title":"BMC Medical Research Methodology"},{"issue":"7","key":"10.1002\/14651858.CD010685.pub2-BIB134|cit134","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD010685","article-title":"Retinoic acid post consolidation therapy for high-risk neuroblastoma","author":"Peinemann","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd010685.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,8,25]],"date-time":"2017-08-25T00:00:00Z","timestamp":1503619200000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD010685.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T18:47:16Z","timestamp":1628534836000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD010685.pub2"}},"subtitle":[],"editor":[{"given":"Frank","family":"Peinemann","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,1,29]]},"references-count":134,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010685.pub2","relation":{},"subject":[],"published":{"date-parts":[[2015,1,29]]}}}